Leap Total Current Assets vs Accounts Payable Analysis

LPTX Stock

USD 3.30 0.14 4.43%

Leap Therapeutics financial indicator trend analysis is infinitely more than just investigating Leap Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Leap Therapeutics is a good investment. Please check the relationship between Leap Therapeutics Total Current Assets and its Accounts Payable accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Leap Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Leap Stock please use our How to Invest in Leap Therapeutics guide.

Total Current Assets vs Accounts Payable

Total Current Assets vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Leap Therapeutics Total Current Assets account and Accounts Payable. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Leap Therapeutics' Total Current Assets and Accounts Payable is 0.44. Overlapping area represents the amount of variation of Total Current Assets that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Leap Therapeutics, assuming nothing else is changed. The correlation between historical values of Leap Therapeutics' Total Current Assets and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Assets of Leap Therapeutics are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Total Current Assets i.e., Leap Therapeutics' Total Current Assets and Accounts Payable go up and down completely randomly.

Correlation Coefficient

0.44

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Total Current Assets

The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.

Accounts Payable

An accounting item on the balance sheet that represents Leap Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Leap Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most indicators from Leap Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Leap Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Leap Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Leap Stock please use our How to Invest in Leap Therapeutics guide.Selling General Administrative is likely to drop to about 8.7 M in 2024. Tax Provision is expected to grow at the current pace this year

Leap Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Net Tangible Assets	Other Assets	Property Plant Equipment	Short Term Debt
Total Assets		0.59	0.02	0.81	0.17	-0.92	-0.64	0.45	0.96	-0.27	-0.1	1.0	0.11	0.8	0.59	-0.28	0.44	0.74	0.33	0.23	1.0	0.29	0.69	0.08	-0.05	-0.34
Other Current Liab	0.59		0.41	0.32	0.29	-0.55	-0.72	0.76	0.6	0.41	0.03	0.57	0.41	0.5	0.57	-0.54	0.12	0.72	0.76	0.38	0.57	-0.01	0.6	0.54	0.28	-0.12
Total Current Liabilities	0.02	0.41		-0.51	-0.09	0.14	-0.31	0.48	0.05	0.38	0.52	-0.01	0.83	0.09	0.2	0.17	-0.34	0.13	0.27	-0.06	0.01	-0.89	-0.27	0.67	-0.02	0.81
Total Stockholder Equity	0.81	0.32	-0.51		0.27	-0.89	-0.52	0.28	0.77	-0.35	-0.31	0.83	-0.37	0.74	0.55	-0.41	0.5	0.69	0.17	0.32	0.82	0.77	0.8	-0.21	0.14	-0.79
Property Plant And Equipment Net	0.17	0.29	-0.09	0.27		-0.2	-0.31	0.31	0.15	0.6	0.16	0.16	-0.24	0.26	0.15	-0.3	0.06	0.35	0.05	0.98	0.15	0.28	0.27	0.25	0.65	-0.32
Net Debt	-0.92	-0.55	0.14	-0.89	-0.2		0.72	-0.54	-0.95	0.29	0.23	-0.92	0.03	-0.84	-0.71	0.51	-0.53	-0.83	-0.4	-0.27	-0.92	-0.48	-0.88	-0.01	-0.07	0.55
Retained Earnings	-0.64	-0.72	-0.31	-0.52	-0.31	0.72		-0.94	-0.67	-0.12	-0.31	-0.63	-0.27	-0.87	-0.92	0.46	0.06	-0.97	-0.6	-0.43	-0.64	-0.14	-0.6	-0.62	-0.46	0.26
Accounts Payable	0.45	0.76	0.48	0.28	0.31	-0.54	-0.94		0.52	0.3	0.36	0.43	0.43	0.69	0.82	-0.46	-0.1	0.87	0.67	0.41	0.44	-0.05	0.5	0.7	0.5	-0.1
Cash	0.96	0.6	0.05	0.77	0.15	-0.95	-0.67	0.52		-0.29	-0.15	0.96	0.13	0.77	0.61	-0.42	0.5	0.75	0.42	0.22	0.96	0.29	0.77	0.09	-0.07	-0.35
Non Current Assets Total	-0.27	0.41	0.38	-0.35	0.6	0.29	-0.12	0.3	-0.29		0.26	-0.3	0.22	-0.13	-0.03	-0.26	-0.23	0.07	0.19	0.56	-0.29	-0.28	-0.06	0.5	0.47	0.22
Non Currrent Assets Other	-0.1	0.03	0.52	-0.31	0.16	0.23	-0.31	0.36	-0.15	0.26		-0.11	0.45	0.1	0.09	0.29	-0.75	0.12	0.16	0.16	-0.1	-0.41	-0.5	0.79	0.16	0.34
Cash And Short Term Investments	1.0	0.57	-0.01	0.83	0.16	-0.92	-0.63	0.43	0.96	-0.3	-0.11		0.08	0.8	0.59	-0.28	0.44	0.73	0.31	0.23	1.0	0.32	0.69	0.06	-0.05	-0.37
Net Receivables	0.11	0.41	0.83	-0.37	-0.24	0.03	-0.27	0.43	0.13	0.22	0.45	0.08		0.08	0.15	0.13	-0.19	0.12	0.47	-0.25	0.11	-0.72	-0.18	0.5	-0.14	0.64
Common Stock Total Equity	0.8	0.5	0.09	0.74	0.26	-0.84	-0.87	0.69	0.77	-0.13	0.1	0.8	0.08		0.91	-0.31	0.17	0.92	0.26	0.37	0.8	0.27	0.64	0.27	0.37	-0.33
Common Stock Shares Outstanding	0.59	0.57	0.2	0.55	0.15	-0.71	-0.92	0.82	0.61	-0.03	0.09	0.59	0.15	0.91		-0.41	0.04	0.92	0.4	0.29	0.59	0.17	0.62	0.38	0.49	-0.26
Non Current Liabilities Total	-0.28	-0.54	0.17	-0.41	-0.3	0.51	0.46	-0.46	-0.42	-0.26	0.29	-0.28	0.13	-0.31	-0.41		-0.42	-0.52	-0.59	-0.34	-0.28	-0.44	-0.75	-0.11	-0.24	0.53
Other Current Assets	0.44	0.12	-0.34	0.5	0.06	-0.53	0.06	-0.1	0.5	-0.23	-0.75	0.44	-0.19	0.17	0.04	-0.42		0.12	-0.05	0.03	0.44	0.36	0.63	-0.67	-0.15	-0.32
Other Stockholder Equity	0.74	0.72	0.13	0.69	0.35	-0.83	-0.97	0.87	0.75	0.07	0.12	0.73	0.12	0.92	0.92	-0.52	0.12		0.53	0.46	0.73	0.31	0.75	0.45	0.44	-0.42
Total Liab	0.33	0.76	0.27	0.17	0.05	-0.4	-0.6	0.67	0.42	0.19	0.16	0.31	0.47	0.26	0.4	-0.59	-0.05	0.53		0.12	0.33	0.07	0.45	0.53	0.12	-0.22
Property Plant And Equipment Gross	0.23	0.38	-0.06	0.32	0.98	-0.27	-0.43	0.41	0.22	0.56	0.16	0.23	-0.25	0.37	0.29	-0.34	0.03	0.46	0.12		0.22	0.3	0.34	0.31	0.73	-0.34
Total Current Assets	1.0	0.57	0.01	0.82	0.15	-0.92	-0.64	0.44	0.96	-0.29	-0.1	1.0	0.11	0.8	0.59	-0.28	0.44	0.73	0.33	0.22		0.3	0.69	0.07	-0.06	-0.35
Common Stock	0.29	-0.01	-0.89	0.77	0.28	-0.48	-0.14	-0.05	0.29	-0.28	-0.41	0.32	-0.72	0.27	0.17	-0.44	0.36	0.31	0.07	0.3	0.3		0.59	-0.39	0.23	-0.99
Net Tangible Assets	0.69	0.6	-0.27	0.8	0.27	-0.88	-0.6	0.5	0.77	-0.06	-0.5	0.69	-0.18	0.64	0.62	-0.75	0.63	0.75	0.45	0.34	0.69	0.59		-0.09	0.19	-0.66
Other Assets	0.08	0.54	0.67	-0.21	0.25	-0.01	-0.62	0.7	0.09	0.5	0.79	0.06	0.5	0.27	0.38	-0.11	-0.67	0.45	0.53	0.31	0.07	-0.39	-0.09		0.27	0.25
Property Plant Equipment	-0.05	0.28	-0.02	0.14	0.65	-0.07	-0.46	0.5	-0.07	0.47	0.16	-0.05	-0.14	0.37	0.49	-0.24	-0.15	0.44	0.12	0.73	-0.06	0.23	0.19	0.27		-0.26
Short Term Debt	-0.34	-0.12	0.81	-0.79	-0.32	0.55	0.26	-0.1	-0.35	0.22	0.34	-0.37	0.64	-0.33	-0.26	0.53	-0.32	-0.42	-0.22	-0.34	-0.35	-0.99	-0.66	0.25	-0.26

Click cells to compare fundamentals

Leap Therapeutics Account Relationship Matchups

Leap Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	7.4M	54.4M	117.9M	70.4M	72.8M	45.2M
Other Current Liab	3.4M	3.0M	4.9M	4.7M	5.7M	3.0M
Total Current Liabilities	8.5M	7.4M	10.0M	11.2M	12.7M	9.7M
Total Stockholder Equity	(1.7M)	46.7M	107.9M	58.9M	60.1M	63.1M
Property Plant And Equipment Net	1.2M	593K	495K	689K	262K	444.1K
Net Debt	(2.9M)	(51.5M)	(114.4M)	(64.8M)	(70.4M)	(66.9M)
Retained Earnings	(195.2M)	(223.0M)	(263.6M)	(318.2M)	(399.6M)	(379.6M)
Accounts Payable	4.6M	2.7M	4.2M	5.7M	6.5M	6.8M
Cash	3.9M	52.1M	114.9M	65.5M	70.6M	38.1M
Non Current Assets Total	3.2M	2.1M	1.0M	2.4M	1.2M	1.9M
Non Currrent Assets Other	1.9M	1.3M	383K	1.7M	966K	1.3M
Cash And Short Term Investments	3.9M	52.1M	114.9M	65.5M	70.6M	42.0M
Net Receivables	185K	73K	1.2M	2.1M	771K	1.0M
Common Stock Total Equity	15K	24K	60K	88K	101.2K	106.3K
Common Stock Shares Outstanding	2.3M	5.9M	8.6M	11.3M	20.4M	21.5M
Liabilities And Stockholders Equity	7.4M	54.4M	117.9M	70.4M	72.8M	45.2M
Non Current Liabilities Total	3.4M	711K	348K	37K	262K	0.0
Other Current Assets	165K	130K	769K	351K	183K	284.3K
Other Stockholder Equity	193.3M	270.2M	371.6M	376.8M	459.6M	482.6M
Total Liab	9.2M	7.7M	10.0M	11.5M	12.7M	8.8M
Property Plant And Equipment Gross	1.2M	593K	495K	689K	483K	464.4K
Total Current Assets	4.2M	52.3M	116.9M	68.0M	71.6M	43.3M
Accumulated Other Comprehensive Income	76K	(579K)	(267K)	128K	106K	100.7K
Common Stock	24K	60K	88K	99K	26K	27.3K
Net Tangible Assets	(1.7M)	46.7M	107.9M	58.9M	67.7M	71.1M
Other Assets	2.1M	2.0M	542K	1.7M	2.0M	1.5M
Property Plant Equipment	1.2M	65K	36K	689K	792.4K	832.0K
Capital Surpluse	162.4M	193.3M	270.2M	371.6M	427.4M	448.8M
Deferred Long Term Liab	162K	831K	345K	576K	518.4K	442.1K
Non Current Liabilities Other	3.4M	159K	348K	37K	33.3K	31.6K
Retained Earnings Total Equity	(153.5M)	(195.2M)	(223.0M)	(263.6M)	(237.2M)	(249.1M)
Net Invested Capital	(1.7M)	46.7M	107.9M	58.9M	60.1M	45.9M
Net Working Capital	(4.2M)	44.9M	106.9M	56.7M	58.9M	46.5M
Capital Stock	24K	60K	88K	99K	26K	24.7K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Leap Stock Analysis

When running Leap Therapeutics' price analysis, check to measure Leap Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Leap Therapeutics is operating at the current time. Most of Leap Therapeutics' value examination focuses on studying past and present price action to predict the probability of Leap Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Leap Therapeutics' price. Additionally, you may evaluate how the addition of Leap Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Leap Total Current Assets vs Accounts Payable Analysis

Total Current Assets vs Accounts Payable

Total Current Assets vs Accounts Payable Correlation Analysis

Correlation Coefficient

Total Current Assets

Accounts Payable

Leap Therapeutics fundamental ratios Correlations

Leap Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Leap Therapeutics fundamental ratios Accounts

Also Currently Popular

Additional Tools for Leap Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Cash And Short Term Investments
Property Plant And Equipment Gross	+ 0.98	Property Plant And Equipment Net
Cash	+ 0.96	Total Assets
Cash And Short Term Investments	+ 0.96	Cash

Short Term Debt	- 0.99	Common Stock
Other Stockholder Equity	- 0.97	Retained Earnings
Cash	- 0.95	Net Debt
Accounts Payable	- 0.94	Retained Earnings
Common Stock Shares Outstanding	- 0.92	Retained Earnings
Total Current Assets	- 0.92	Net Debt